Related Experiment Video

Updated: Aug 19, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent

E García Vázquez1, J Mensa, J A Martínez

  • 1Infectious Diseases Department, Hospital Clinic Universitari, Barcelona, Spain. elisag@eresmas.net

European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology
|March 23, 2005
PubMed

Insights

Adding a macrolide antibiotic to beta-lactam therapy for community-acquired pneumonia significantly lowers mortality rates. This combination therapy is recommended for empirical treatment, regardless of infection severity.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Clinical Medicine

Background:

  • Community-acquired pneumonia (CAP) poses a significant public health challenge.
  • Empirical antibiotic selection is crucial for CAP management.
  • The role of macrolides in combination therapy for CAP requires further investigation.

Purpose of the Study:

  • To evaluate the impact of adding a macrolide to beta-lactam empirical treatment on mortality rates in CAP patients.
  • To determine if this combination therapy improves outcomes independently of disease severity.

Main Methods:

  • A cohort of 1,391 patients with CAP of various etiologies were studied.
  • Patients were treated with either a beta-lactam agent alone or a beta-lactam agent plus a macrolide.
  • Pneumonia severity was assessed using the PORT score; intensive care unit patients were excluded.

Main Results:

  • The mortality rate was 13.3% with beta-lactam monotherapy versus 6.9% with combination therapy (p=0.001).
  • Combination therapy was associated with a lower proportion of severe cases (PORT-group V).
  • Adjusted analysis revealed a two-fold higher odds of fatal outcome with beta-lactam monotherapy (aOR=2).

Conclusions:

  • Addition of a macrolide to beta-lactam empirical therapy is associated with reduced mortality in CAP.
  • This benefit appears independent of the pneumonia severity score (PORT score).
  • Results support the recommendation of beta-lactam-macrolide combination therapy for empirical CAP treatment.

Related Concept Videos

Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Inhibitors of Gram-positive Cell Wall Synthesis01:23

Inhibitors of Gram-positive Cell Wall Synthesis

Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...